1. Neuronal Signaling
  2. Monoamine Oxidase
  3. Rasagiline

Rasagiline (Synonyms: AGN1135; TVP1012)

Cat. No.: HY-14605A
Handling Instructions

Rasagiline(AGN1135;TVP1012) is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease.

For research use only. We do not sell to patients.

Rasagiline Chemical Structure

Rasagiline Chemical Structure

CAS No. : 136236-51-6

Size Price Stock
50 mg USD 100 Ask For Quote & Lead Time
100 mg USD 130 Ask For Quote & Lead Time
250 mg USD 200 Ask For Quote & Lead Time

* Please select Quantity before adding items.

Other In-stock Forms of Rasagiline:

Other Forms of Rasagiline:

Top Publications Citing Use of Products

    Rasagiline purchased from MCE. Usage Cited in: Oncotarget. 2018 Jan 30;9(15):12137-12153.

    Retinal protection of Rasagiline combined with Idebenone against retinal ischemia-reperfusion (RIR) injury. Western blot analysis for the expression level of brain-derived neurotrophic factor (BDNF) in the whole IR-injured retinas.

    View All Monoamine Oxidase Isoform Specific Products:

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review


    Rasagiline(AGN1135;TVP1012) is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease. Target: Monoamine Oxidase (MAO)-B Rasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug. Rasagiline is effective as monotherapy or adjunct to L-Dopa for patients with early and late Parkinson's disease (PD) [1]. Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early PD and as adjunctive therapy in advanced PD. In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo studies. The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established [2]. Rasagiline has been found to be well tolerated and effective in the treatment of early PD and as adjunctive treatment in motor fluctuations. Whether rasagiline is associated with clinically significant neuroprotection (ie, disease modification) in PD is the subject of ongoing clinical trials [3].

    Clinical Trial
    Molecular Weight




    CAS No.



    C#CCN[[email protected]]1C2=CC=CC=C2CC1


    Room temperature in continental US; may vary elsewhere.


    Please store the product under the recommended conditions in the Certificate of Analysis.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2


    RasagilineAGN1135TVP1012AGN 1135AGN-1135TVP 1012TVP-1012Monoamine OxidaseMAOInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name



    Applicant Name *


    Email address *

    Phone number *


    Organization name *

    Country or Region *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cat. No.:
    MCE Japan Authorized Agent: